Oncology Institute (TOI) Director Kaushal Mohit Receives RSU Award

What Happened
Kaushal Mohit, a director of Oncology Institute, Inc. (TOI), was granted 33,133 restricted stock units (RSUs) on 2026-07-27. The Form 4 records the acquisition as 33,133 shares at $0.00 (total $0) under transaction code "A" (award/grant). This is an equity compensation award, not an open-market purchase or sale.

Key Details

• Transaction date: 2026-07-27; Form 4 filed: 2026-07-29 (filed within the typical two-business-day window).
• Grant amount: 33,133 RSUs; reported price: $0.00; reported total value on Form 4: $0.
• Post-transaction beneficial ownership: Not specified in the provided filing summary.
• Footnote: Each RSU entitles the holder to one share upon settlement. The RSUs vest in full on the date of the Issuer's 2027 annual meeting of stockholders, contingent on Mohit's continued service (per footnote F1).
• Transaction type: Award/grant of RSUs (derivative equity award), not an immediate stock purchase or sale.

Context
RSUs are a form of compensation that convert into actual shares only upon vesting/settlement; they do not represent immediate sale or purchase activity in the open market. Such awards are common for executives and directors and reflect compensation rather than a direct signal of buying or selling intent.